IRIX · XBRL financial data

Iridex financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (IRIX's year ends in early January)

In thousands of dollars	FY 2020Jan 2, 2021	FY 2021Jan 1, 2022	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2024Dec 28, 2024	FY 2025Jan 3, 2026
Revenue from contracts with customers	36,347	53,903	56,972	51,869	48,669	52,675
Cost of revenue	20,789	31,072	31,604	30,062	29,167	33,448
Gross profit	15,558	22,831	25,368	21,807	19,502	19,227
Research and development	3,282	6,868	7,175	6,829	5,449	3,668
General and administrative	6,620	8,859	7,557	8,748	9,776	7,734
Total operating expenses	22,141	30,364	32,910	31,814	27,804	21,798
Operating income (loss)	(6,583)	(7,533)	(7,542)	(10,007)	(8,302)	(2,571)
Interest expense	—	—	—	—	146	58
Income tax expense (benefit)	26	40	65	90	68	57
Net income (loss)	(6,329)	(5,225)	(7,547)	(9,570)	(8,910)	(4,437)
Earnings per share, basic USD per share	(0.46)	(0.34)	(0.47)	(0.59)	(0.54)	(0.26)
Earnings per share, diluted USD per share	(0.46)	(0.34)	(0.47)	(0.59)	(0.54)	(0.26)
Weighted average shares, basic thousands of shares	13,842	15,421	15,938	16,128	16,439	16,934
Weighted average shares, diluted thousands of shares	13,842	15,421	15,938	16,128	16,439	16,934

Fiscal years (IRIX's year ends in early January)

In thousands of dollars	FY 2020Jan 2, 2021	FY 2021Jan 1, 2022	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2024Dec 28, 2024	FY 2025Jan 3, 2026
Cash and cash equivalents	11,626	23,852	13,922	7,034	2,387	6,028
Accounts receivable	7,289	6,610	6,229	6,727	5,951	7,613
Inventory	5,714	7,614	10,608	9,906	10,817	7,877
Prepaid and other current assets	730	1,071	1,468	856	1,964	1,802
Total current assets	25,359	42,253	35,766	27,450	23,562	25,252
Property and equipment, net	449	428	462	351	115	58
Right-of-use asset	1,428	2,565	1,665	2,632	1,792	768
Goodwill	533	965	965	965	965	965
Total assets	27,969	48,687	42,290	34,436	29,135	29,151
Accounts payable	1,148	2,772	3,858	4,499	6,985	5,385
Accrued liabilities	1,806	1,575	1,548	1,996	477	608
Current portion of long-term debt	1,249	—	—	—	—	—
Total current liabilities	8,681	12,646	12,453	12,974	16,559	13,208
Lease liability, non-current	282	1,729	732	1,751	811	98
Total liabilities	10,603	25,388	25,059	24,914	27,038	24,229
Accumulated deficit	(56,944)	(62,169)	(69,716)	(79,042)	(88,009)	(92,446)
Total stockholders' equity	17,366	23,299	17,231	9,522	2,097	4,922
Total liabilities and equity	27,969	48,687	42,290	34,436	29,135	29,151
Common shares outstanding (cover page) thousands of shares	15,521	15,883	16,007	16,253	16,789	17,307

Fiscal years (IRIX's year ends in early January)

In thousands of dollars	FY 2020Jan 2, 2021	FY 2021Jan 1, 2022	FY 2022Dec 31, 2022	FY 2023Dec 30, 2023	FY 2024Dec 28, 2024	FY 2025Jan 3, 2026
Net income (loss)	(6,329)	(5,225)	(7,547)	(9,570)	(8,910)	(4,437)
Net cash from operating activities	(3,237)	8,217	(9,519)	(6,745)	(7,285)	(2,115)
Purchases of property and equipment	97	213	286	109	13	143
Net cash from investing activities	(93)	(5,556)	(286)	(109)	(13)	(143)
Proceeds from issuing common stock	—	9,878	0	—	—	—
Proceeds from long-term debt	2,497	—	—	—	—	—
Net cash from financing activities	2,467	9,466	(73)	(5)	2,605	5,964
Net change in cash	(1,027)	12,226	(9,930)	(6,888)	(4,647)	3,641

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.